Learn About Langerhans Cell Histiocytosis
Langerhans cell histiocytosis is a disorder in which excess immune system cells called Langerhans cells build up in the body. Langerhans cells, which help regulate the immune system, are normally found throughout the body, especially in the skin, lymph nodes, spleen, lungs, liver, and bone marrow. In Langerhans cell histiocytosis, excess immature Langerhans cells usually form tumors called granulomas. Many researchers now consider Langerhans cell histiocytosis to be a form of cancer, but this classification remains controversial.
Somatic mutations in the BRAF gene have been identified in the Langerhans cells of about half of individuals with Langerhans cell histiocytosis. Somatic gene mutations are acquired during a person's lifetime and are present only in certain cells. These changes are not inherited.
Langerhans cell histiocytosis is a rare disorder. Its prevalence is estimated at 1 to 2 in 100,000 people.
Langerhans cell histiocytosis is usually not inherited and typically occurs in people with no history of the disorder in their family.
Mayo Clinic
Jithma Abeykoon is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Abeykoon is rated as an Elite provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Waldenstrom Macroglobulinemia, Reticulohistiocytoma, Histiocytosis, Tissue Biopsy, and Bone Marrow Transplant. Dr. Abeykoon is currently accepting new patients.
Vince Lombardi Cancer Clinic
Syed Abutalib is a Hematologist in Milwaukee, Wisconsin. Dr. Abutalib is rated as a Distinguished provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Langerhans Cell Histiocytosis, Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.
Kenneth Mcclain is a Pediatric Hematologist Oncology provider in Houston, Texas. Dr. Mcclain is rated as an Elite provider by MediFind in the treatment of Langerhans Cell Histiocytosis. His top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Non-Langerhans-Cell Histiocytosis.
Summary: This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic m...
Summary: This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too ma...
Published Date: October 01, 2017
Published By: National Institutes of Health